Immunotherapy

Teclistamab Significantly Lengthens Remissions and Survival in Relapsed Myeloma Trial

The MajesTEC-9 data point to a shift toward earlier use of bispecific immunotherapy by showing deeper, longer remissions that come with an infection risk that can be managed with prophylaxis and monitoring.